Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aprepitant vs Ondansetron for CINV in Cisplatin-Treated Patients
NCT00090207Phase 4
Key facts
- Status
- Completed
- Start
- Jan 2004
- Primary completion
- Sep 2004
- Sponsor
- Merck & Co.
- Modality
- Small Molecules
- Drugs
- aprepitant
- Conditions
- chemotherapy-induced nausea and vomiting (CINV)
01
Overview
Phase 4, randomised, double-blind trial of aprepitant in chemotherapy-induced nausea and vomiting (CINV) (2 arms), sponsored by Merck & Co. Primary endpoint: Patient vomiting. Started Jan 2004; status: completed.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Aprepitant Regimen
Aprepitant + Ondansetron + Dexamethasone
Ondansetron Regimen
Ondansetron + Dexamethasone
03
Who it enrols
Adult patients with solid tumors scheduled to receive their first course of cisplatin chemotherapy and a life expectancy of at least 3 months.
04
Endpoints
Primary
Patient vomiting
Secondary
Number of rescue therapies
Beyond the preview
Go deeper on NCT00090207.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00090207.